Literature DB >> 9155061

Elevated serum levels of S100 and survival in metastatic malignant melanoma.

J Buer1, M Probst, A Franzke, S Duensing, J Haindl, M Volkenandt, F Wittke, R Hoffmann, A Ganser, J Atzpodien.   

Abstract

Current reports suggest serum S100 as a prognostic marker for disease progression in advanced malignant melanoma. In this study, we assessed serum levels of S100 and multiple clinical factors in relation to overall survival in 99 patients with metastatic malignant melanoma seen at our institution between May 1990 and April 1996. For statistical analysis, we used both univariate and multivariate Cox proportional-hazards models. Elevated serum levels of S100 correlated with poor outcome in metastatic malignant melanoma (P < 0.0001), univariate analysis). Upon multivariate analysis, however, S100 added no information to known clinical prognostic parameters.

Entities:  

Mesh：

Substances：

Year:  1997        PMID： 9155061      PMCID： PMC2228235          DOI： 10.1038/bjc.1997.232

Source DB:  PubMed          Journal:  Br J Cancer        ISSN： 0007-0920            Impact factor:   7.640


  15 in total

Review 1.  Cutaneous melanoma.

Authors:  H K Koh
Journal:  N Engl J Med       Date:  1991-07-18       Impact factor: 91.245

Review 2.  Current therapy for malignant melanoma.

Authors:  S S Legha
Journal:  Semin Oncol       Date:  1989-02       Impact factor: 4.929

3.  Particle counting immunoassay of S100 protein in serum. Possible relevance in tumors and ischemic disorders of the central nervous system.

Authors:  O C Fagnart; C J Sindic; C Laterre
Journal:  Clin Chem       Date:  1988-07       Impact factor: 8.327

4.  Structural relation of two S-100 proteins in bovine brain; subunit composition of S-100a protein.

Authors:  T Isobe; N Ishioka; T Okuyama
Journal:  Eur J Biochem       Date:  1981-04

5.  Detection of melanoma cells in peripheral blood by means of reverse transcriptase and polymerase chain reaction.

Authors:  B Smith; P Selby; J Southgate; K Pittman; C Bradley; G E Blair
Journal:  Lancet       Date:  1991-11-16       Impact factor: 79.321

6.  S100 protein: a marker for human malignant melanomas?

Authors:  R Gaynor; H R Herschman; R Irie; P Jones; D Morton; A Cochran
Journal:  Lancet       Date:  1981-04-18       Impact factor: 79.321

7.  Relation of cytogenetic abnormalities and clinical outcome in metastatic melanoma.

Authors:  J M Trent; F L Meyskens; S E Salmon; K Ryschon; S P Leong; J R Davis; D L McGee
Journal:  N Engl J Med       Date:  1990-05-24       Impact factor: 91.245

8.  Prognostic factors in patients with metastatic malignant melanoma. A multivariate analysis.

Authors:  M N Sirott; D F Bajorin; G Y Wong; Y Tao; P B Chapman; M A Templeton; A N Houghton
Journal:  Cancer       Date:  1993-11-15       Impact factor: 6.860

9.  Regression analyses of prognostic factors in metastatic malignant melanoma.

Authors:  K Heimdal; E Hannisdal; S Gundersen
Journal:  Eur J Cancer Clin Oncol       Date:  1989-08

10.  The emerging epidemic of melanoma and squamous cell skin cancer.

Authors:  A G Glass; R N Hoover
Journal:  JAMA       Date:  1989-10-20       Impact factor: 56.272
View more
  12 in total

Review 1.  New insights in melanoma biomarkers: long-noncoding RNAs.

Authors:  Ricardo Moreno-Traspas; Igor Vujic; Martina Sanlorenzo; Susana Ortiz-Urda
Journal:  Melanoma Manag       Date:  2016-08-16

2.  Serum levels of S-100 protein and 5-S-cysteinyldopa as markers of melanoma progression.

Authors:  T Bánfalvi; K Gilde; M Boldizsár; T Kremmer; S Ottó
Journal:  Pathol Oncol Res       Date:  1999       Impact factor: 3.201

Review 3.  Circulating serologic and molecular biomarkers in malignant melanoma.

Authors:  Shanique R Palmer; Lori A Erickson; Ilia Ichetovkin; Daniel J Knauer; Svetomir N Markovic
Journal:  Mayo Clin Proc       Date:  2011-10       Impact factor: 7.616

4.  Prognostic significance of serum S100B protein in high-risk surgically resected melanoma patients participating in Intergroup Trial ECOG 1694.

Authors:  Ahmad A Tarhini; Joseph Stuckert; Sandra Lee; Cindy Sander; John M Kirkwood
Journal:  J Clin Oncol       Date:  2008-12-01       Impact factor: 44.544

5.  Tumour assessment in advanced melanoma: value of FDG-PET/CT in patients with elevated serum S-100B.

Authors:  Klaus Strobel; Jeannine Skalsky; Victor Kalff; Katrin Baumann; Burkhardt Seifert; Helen Joller-Jemelka; Reinhard Dummer; Hans C Steinert
Journal:  Eur J Nucl Med Mol Imaging       Date:  2007-03-28       Impact factor: 9.236

6.  Comparison of prognostic significance of serum 5-S-Cysteinyldopa, LDH and S-100B protein in Stage III-IV malignant melanoma.

Authors:  Teodóra Bánfalvi; Mariann Boldizsár; Maria Gergye; Katalin Gilde; Tibor Kremmer; Szabolcs Ottó
Journal:  Pathol Oncol Res       Date:  2003-01-06       Impact factor: 3.201

7.  Covalent small molecule inhibitors of Ca(2+)-bound S100B.

Authors:  Michael C Cavalier; Adam D Pierce; Paul T Wilder; Milad J Alasady; Kira G Hartman; David B Neau; Timothy L Foley; Ajit Jadhav; David J Maloney; Anton Simeonov; Eric A Toth; David J Weber
Journal:  Biochemistry       Date:  2014-10-14       Impact factor: 3.162

Review 8.  Biomarkers in melanoma.

Authors:  H Gogas; A M M Eggermont; A Hauschild; P Hersey; P Mohr; D Schadendorf; A Spatz; R Dummer
Journal:  Ann Oncol       Date:  2009-08       Impact factor: 32.976

Review 9.  Staging of cutaneous melanoma.

Authors:  P Mohr; A M M Eggermont; A Hauschild; A Buzaid
Journal:  Ann Oncol       Date:  2009-08       Impact factor: 32.976

10.  S-100B concentrations predict disease-free survival in stage III melanoma patients.

Authors:  S Kruijff; E Bastiaannet; A C Muller Kobold; R J van Ginkel; A J H Suurmeijer; H J Hoekstra
Journal:  Ann Surg Oncol       Date:  2009-12       Impact factor: 5.344
View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.